We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

SAND:OMXSTOSandvik AB Analysis

Data as of 2026-07-30 - not real-time

$1,015.89

Latest Price

8/10Risk

Risk Level: High

Executive Summary

The short‑term SMA is above the medium‑term SMA, suggesting downward bias. The RSI is in the oversold region, hinting at potential bounce. The MACD line sits below its signal, reinforcing bearish momentum. Price is hugging a key support level while resistance sits well above. Beta is exceptionally high, indicating amplified market moves. Recent volatility has spiked to extreme levels. The DCF model places fair value far below current price, implying overvaluation. Forward earnings multiple is dramatically lower than trailing, suggesting expected earnings acceleration. Market sentiment is at extreme greed, which can precede a pullback. Liquidity remains solid with rising volume.
Fundamentally, the company posts robust gross and operating margins, strong cash generation, and minimal debt, delivering high returns on equity and assets. However, the lack of dividend means income investors have limited appeal. Analyst consensus leans bullish, but price disparity raises caution. Geographic exposure is broad, mitigating single‑region shocks, though regulatory headwinds in key markets could arise. Overall risk is elevated by volatility and beta, while liquidity risk is low. Given these dynamics, a cautious stance is warranted.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • bearish MACD alignment
  • price near key support
  • elevated short‑term volatility

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • significant overvaluation relative to DCF
  • strong cash generation and margins
  • forward earnings upside potential

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • price far above fair value
  • high beta and persistent volatility
  • absence of dividend reduces long‑term income appeal

Key Metrics & Analysis

Financial Health

Revenue Growth251.00%
Profit Margin34.19%
P/E Ratio34.7
ROE39.30%
ROA22.82%
Debt/Equity1.50
P/B Ratio10.9
Op. Cash Flow$4.6B
Free Cash Flow$2.3B
Industry P/E31.2

Technical Analysis

TrendNeutral
RSI32.8
Support$998.19
Resistance$2,129.98
MA 20$1,573.51
MA 50$1,713.65
MA 200$831.87
MACDBearish
VolumeIncreasing
Fear & Greed Index84.54

Valuation

Fair Value$563.20
Target Price$2,217.77
Upside/Downside118.31%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta4.16
Volatility149.88%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.